WE INVEST IN LIFE
Ridgeline, a Versant Ventures Discovery Engine located in Switzerland, creates new biotech companies in partnership with entrepreneurs, industry and leading academics across Europe, US and RoW.
ABOUT US
Ridgeline, a Versant Ventures Discovery Engine, creates and operates Versant-financed innovative biotech companies in partnership with entrepreneurs, industry, and leading academics across Europe, US and RoW. In recent years, Ridgeline has assembled an international team of highly experienced drug discovery and industry professionals and built and operated multiple new successful companies; these companies have raised significant funds through Series B, IPO, Pharma Partnerships and an exit through a trade sale.
Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.5 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 100 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com.
VERSANT DISCOVERY ENGINES
Accessing the best science and innovation
RIDGELINE - A VERSANT VENTURES DISCOVERY ENGINE
SOURCE
We partner with entrepreneurs and leading academics across Europe, US and RoW to access breakthrough transformational science that serves as the foundation of our company creation efforts.
DISCOVER
Together with our academic founders, our international team of accomplished industry R&D veterans drives research to create novel platforms and high-quality therapeutic candidates.
BUILD
Our international team has deep investment, research and operating experience that enables an efficient, hands-on approach to company building and value creation.
RIDGELINE BUILDS
COMPANIES
Ridgeline is a Versant Ventures Discovery Engine. Founded in 2017, Ridgeline has the mission to build new leading biotech companies, operate them, help them to grow and establish their own independent footprint. These include Black Diamond Therapeutics, Bright Peak Therapeutics, and Monte Rosa Therapeutics which operate fully independently. Several more recently founded companies, including Cimeio Therapeutics, Red Ridge Bio, and SixPeaks Bio are operating in collaboration with Ridgeline.
Novel platforms, breakthrough therapies
LEADERSHIP
Brad Bolzon, Ph.D.
Chairman and Managing Director at Versant Ventures
Ridgeline Discovery Board Member
Alexander Mayweg, Ph.D.
Managing Director at Versant Ventures
President and Ridgeline Discovery Board Member
Markus Enzelberger, Ph.D.
Partner at Versant Ventures
Ridgeline Discovery Board Member
GET IN TOUCH
OFFICES
Ridgeline Discovery GmbH
c/o Versant Ventures
Aeschenvorstadt 36
CH 4051 Basel
Switzerland
info@ridgelinediscovery.com
OFFICES AND LABS
Ridgeline Discovery GmbH
Technologiepark
Hochbergerstrasse 60 F
CH 4057 Basel
Switzerland
info@ridgelinediscovery.com